Insulin Access: Eliminating Costs for Medicare and Medicaid
This bill aims to eliminate all cost-sharing, such as deductibles, copayments, or coinsurance, for insulin and associated injection supplies for individuals covered by Medicare and Medicaid programs. This means patients will not have to bear additional costs for these essential medications and accessories, potentially significantly reducing their diabetes treatment expenses.
Key points
No cost-sharing for insulin and injection supplies for Medicare beneficiaries starting January 1, 2022.
No cost-sharing for insulin and injection supplies for Medicaid beneficiaries starting January 1, 2022.
The act aims to improve access to insulin and reduce financial burdens for people with diabetes.
Expired
Citizen Poll